MET and cancer: Tepotinib, a highly selective oral cMET inhibitor, was well tolerated, has shown promising efficacy in advanced hepatocellular carcinoma patients with cMET overexpression, and is currently being investigated for other cMET-deregulated cancers (42, 43).